^
    Apply
    Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus (OP-1250-003) (NCT05508906)
    Phase 1
    Olema Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    10/03/2024
    Initiation :
    08/31/2022
    Primary completion :
    05/20/2026
    Completion :
    06/30/2026
    HER-2
    |
    HER-2 negative
    |
    everolimus • Piqray (alpelisib) • Kisqali (ribociclib) • palazestrant (OP-1250)
    OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01) (NCT06016738)
    Phase 3
    Olema Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    11/16/2023
    Primary completion :
    06/30/2026
    Completion :
    09/30/2027
    HER-2 • ER
    |
    HER-2 negative • ESR1 mutation
    |
    fulvestrant • letrozole • anastrozole • exemestane • palazestrant (OP-1250)